Fighting fire with fire: Is it time to use probiotics to manage pathogenic bacterial diseases?

Current Gastroenterology Reports

Volumn 14, Issue 4, 2012, Pages 343-348

  Heineman, John ^a   Bubenik, Sara ^a   McClave, Stephen ^b   Martindale, Robert ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Anti inflammatory; Antimicrobial; Probiotics; Treatment

Indexed keywords

METRONIDAZOLE; PLACEBO; PROBIOTIC AGENT; VANCOMYCIN;

ARTICLE; BACTERIAL INFECTION; BIFIDOBACTERIUM BIFIDUM; BIFIDOBACTERIUM LONGUM INFANTIS; CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; ENTEROCOCCAL INFECTION; HELICOBACTER INFECTION; HUMAN; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS BULGARICUS; LACTOBACILLUS CASEI; LACTOBACILLUS RHAMNOSUS; LOW DRUG DOSE; NECROTIZING ENTEROCOLITIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; SACCHAROMYCES BOULARDII; STREPTOCOCCUS THERMOPHILUS; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA;

BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS; ENTEROCOLITIS, NECROTIZING; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PNEUMONIA, VENTILATOR-ASSOCIATED; PROBIOTICS; VANCOMYCIN;

EID: 84865655866     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-012-0274-4     Document Type: Article

References (49)

1. Fuller R. Probiotics in human medicine. Ann Med. 1990;22:37-41.
2. Loprinzi CL, Levitt R, Barton DL, et al. Evaluation of shark cartilage in patients with advanced cancer: A north central cancer treatment group trial. Cancer. 2005;104(1):176-82. (Pubitemid 40847766)
3. Bassler W. Civ. no. 99-5782 (WGB). US District Court for the District of New Jersey. 2004.
4. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347(15):1175-86.
5. Chey WD, Wong BC. Practice Parameters Committee of the American College of Gastroenterology. American college of gastroenterology guideline on the management of helicobacter pylori infection. Am J Gastroenterol. 2007;102(8):1808-25. (Pubitemid 47206706)
6. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59(8):1143-53.
7. Michetti P, Dorta G, Wiesel PH, et al. Effect of whey-based culture supernatant of lactobacillus acidophilus (johnsonii) La1 on helicobacter pylori infection in humans. Digestion. 1999;60(3):203-9. (Pubitemid 29221886)
8. Mukai T, Tomoko A, Sato E, et al. Inhibition of binding of heliobacter pylori to the glycolipid receptors by probiotic lactobacillus reuteri. Immunol Med Microbiol. 2001;32:105-10. (Pubitemid 34124108)
9. Lorca GL, Wadstrom T, Valdez GF, Ljungh A. Lactobacillus acidophilus autolysins inhibit helicobacter pylori in vitro. Curr Microbiol. 2001;42(1):39-44. (Pubitemid 32225766)
10. Collado MC, Gonzalez A, Gonzalez R, Hernandez M, Ferrus MA, Sanz Y. Antimicrobial peptides are among the antagonistic metabolites produced by bifidobacterium against helicobacter pylori. Int J Antimicrob Agents. 2005;25(5):385-91. (Pubitemid 40558769)
11. Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analysis: The effect of supplementation with probiotics on eradication rates and adverse events during helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007;25(2):155-68. (Pubitemid 46046372)
12. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: The effects of saccharomyces boulardii supplementation on helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010;32(9):1069-79.
13. Cindoruk M, Erkan G, Karakan T, Dursun A, Unal S. Efficacy and safety of saccharomyces boulardii in the 14-day triple antihelicobacter pylori therapy: A prospective randomized placebocontrolled double-blind study. Helicobacter. 2007;12(4):309-16. (Pubitemid 47196340)
14. Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: A parallel group, triple blind, placebo-controlled study. Am J Gastroenterol. 2002;97(11):2744-9. (Pubitemid 35265423)
15. Duman DG, Bor S, Ozutemiz O, et al. Efficacy and safety of saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to helicobacterpylori eradication. Eur J Gastroenterol Hepatol. 2005;17(12):1357-61. (Pubitemid 41830458)
16. Hurduc V, Plesca D, Dragomir D, Sajin M, Vandenplas Y. A randomized, open trial evaluating the effect of saccharomyces boulardii on the eradication rate of helicobacter pylori infection in children. Acta Paediatr. 2009;98(1):127-31.
17. Song MJ, Park DI, Park JH, et al. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of helicobacter pylori. Helicobacter. 2010;15(3):206-13.
18. Kelesidis T, Pothoulakis C. Efficacy and safety of the probiotic saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therap Adv Gastroenterol. 2012;5(2):111-25.
19. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant staphylococcus aureus, enterococcus, gram-negative bacilli, clostridium difficile, and candida. Ann Intern Med. 2002;136(11):834-44. (Pubitemid 34568654)
20. Drekonja DM, Butler M, MacDonald R, et al. Comparative effectiveness of clostridium difficile treatments: A systematic review. Ann Intern Med. 2011;155(12):839-47.
21. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of saccharomyces boulardii in combination with standard antibiotics for clostridium difficile disease. JAMA. 1994;271(24):1913-8. (Pubitemid 24177098)
22. Surawicz C, McFarland L, Greenberg R. The search for a better treatment for recurrent clostridium difficile disease: Use of highdose vancomycin combine with saccharomyces boulardii. Clin Infect Dis. 2000;31:1012-1017. (Pubitemid 32299362)
23. Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent clostridium difficile disease. J Med Microbiol. 2005;54(Pt 9):905-6. (Pubitemid 41216291)
24. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of clostridium difficile disease. Am J Gastroenterol. 2006;101(4):812-22. Curr Gastroenterol Rep (2012) 14:343-348 347
25. Hickson M, D'Souza AL, Muthu N, et al. Use of probiotic lactobacillus preparation to prevent diarrhoea associated with antibiotics: Randomised double blind placebo controlled trial. BMJ. 2007;335(7610):80.
26. Pillai A, Nelson R. Probiotics for treatment of clostridium difficileassociated colitis in adults. Cochrane Database Syst Rev. 2008; (1)(1):CD004611.
27. Thilo E, Rosenberg A. The newborn infant. Current Diagnosis & Treatment (20th Edition): Pediatrics. 2011.
28. Frost BL, Caplan MS. Probiotics and prevention of neonatal necrotizing enterocolitis. Curr Opin Pediatr. 2011;23(2): 151-5.
29. Bin-Nun A, Bromiker R, Wilschanski M, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr. 2005;147(2):192-6. (Pubitemid 41207832)
30. Lin HC, Hsu CH, Chen HL, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: A multicenter, randomized, controlled trial. Pediatrics. 2008;122 (4):693-700.
31. Deshpande G, Rao S, Patole S, Bulsara M. Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics. 2010;125(5):921-30.
32. Alfaleh K, Anabrees J, Bassler D, Al-Kharfi T. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. 2011;(3)(3):CD005496.
33. Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia: A blinded, randomized, controlled trial. Am J Respir Crit Care Med. 2010;182(8):1058-64.
34. Sachdev G, Napolitano LM. Postoperative pulmonary complications: Pneumonia and acute respiratory failure. Surg Clin North Am. 2012;92(2):321-44, ix.
35. Napolitano LM. Perspectives in surgical infections: What does the future hold? Surg Infect (Larchmt). 2010;11(2):111-23.
36. Klarin B, Molin G, Jeppsson B, Larsson A. Use of the probiotic lactobacillus plantarum 299 to reduce pathogenic bacteria in the oropharynx of intubated patients: A randomised controlled open pilot study. Crit Care. 2008;12(6):R136.
37. Siempos II, Ntaidou TK, Falagas ME. Impact of the administration of probiotics on the incidence of ventilator-associated pneumonia: A meta-analysis of randomized controlled trials. Crit Care Med. 2010;38(3):954-62.
38. Schultz MJ, Haas LE. Antibiotics or probiotics as preventive measures against ventilator-associated pneumonia: A literature review. Crit Care. 2011;15(1):R18.
39. Vidal M, Forestier C, Charbonnel N, Henard S, Rabaud C, Lesens O. Probiotics and intestinal colonization by vancomycin-resistant enterococci in mice and humans. J Clin Microbiol. 2010;48 (7):2595-8.
40. Kim AS. Using the good to beat out the bad: Probiotics for eliminating vancomycin-resistant enterococci colonization. J Clin Gastroenterol. 2011;45(10):844-5.
41. Mlynarczyk A, Szymanek-Majchrzak K, Kosykowska E, et al. The dominant sequence types of vancomycin-resistant enterococcus faecium among transplantation ward patients. Transplant Proc. 2011;43(8):3132-4.
42. Manley KJ, Fraenkel MB, Mayall BC, Power DA. Probiotic treatment of vancomycin-resistant enterococci: A randomised controlled trial. Med J Aust. 2007;186(9):454-7. (Pubitemid 46806821)
43. Szachta P, Ignys I, Cichy W. An evaluation of the ability of the probiotic strain lactobacillus rhamnosus GG to eliminate the gastrointestinal carrier state of vancomycin-resistant enterococci in colonized children. J Clin Gastroenterol. 2011;45(10):872-7.
44. Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the united states in 1999-2002. Am J Gastroenterol. 2006;101(1):76-82. (Pubitemid 43381712)
45. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology. 2002;122(6):1649-57. (Pubitemid 34533559)
46. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003;37(2):343-50. (Pubitemid 36152533)
47. Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des. 2009;15 (13):1546-58.
48. Loguercio C, Federico A, Tuccillo C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol. 2005;39(6): 540-3. (Pubitemid 40863651)
49. Lirussi F, Mastropasqua E, Orando S. No evidence to support or refute probiotics for patients with non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database of Systematic Reviews. 2007;CD005165.